Aiping Shi
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (NCT05088057) | Aiping Shi | 2021-09-20 |
Track Aiping Shi automatically
Every clearance here is in the API, with alerts when new ones post.